Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/245369
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Carmen, Sofía del | - |
dc.contributor.author | Sayagués, José María | - |
dc.contributor.author | Bengoechea, Óscar | - |
dc.contributor.author | Anduaga, María Fernanda | - |
dc.contributor.author | Alcazar, Jose Antonio | - |
dc.contributor.author | Gervas, Ruth | - |
dc.contributor.author | García, Jacinto | - |
dc.contributor.author | Orfao, Alberto | - |
dc.contributor.author | Muñoz-Bellvis, Luís | - |
dc.contributor.author | Sarasquete, María Eugenia | - |
dc.contributor.author | Abad, María del Mar | - |
dc.date.accessioned | 2021-07-06T18:40:10Z | - |
dc.date.available | 2021-07-06T18:40:10Z | - |
dc.date.issued | 2018-09-28 | - |
dc.identifier.citation | Oncotarget 9(76): 34279-34288 (2018) | - |
dc.identifier.uri | http://hdl.handle.net/10261/245369 | - |
dc.description.abstract | It is well known that activating mutations in the KRAS and NRAS genes are associated with poor response to anti-EGFR therapies in patients with metastatic colorectal cancer (mCRC). Approximately half of the patients with wild-type (WT) KRAS colorectal carcinoma do not respond to these therapies. This could be because the treatment decision is determined by the mutational profile of the primary tumor, regardless of the presence of small tumor subclones harboring RAS mutations in lymph nodes or liver metastases. We analyzed the mutational profile of the KRAS, NRAS, BRAF and PI3KCA genes using low-density microarray technology in samples of 26 paired primary tumors, 16 lymph nodes and 34 liver metastases from 26 untreated mCRC patients (n=76 samples). The most frequent mutations found in primary tumors were KRAS (15%) and PI3KCA (15%), followed by NRAS (8%) and BRAF (4%). The distribution of the mutations in the 16 lymph node metastases analyzed was as follows: 4 (25%) in KRAS gene, 3 (19%) in NRAS gene and 1 mutation each in PI3KCA and BRAF genes (6%). As expected, the most prevalent mutation in liver metastasis was in the KRAS gene (35%), followed by PI3KCA (9%) and BRAF (6%). Of the 26 cases studied, 15 (58%) displayed an overall concordance in the mutation status detected in the lymph node metastases and liver metastases compared with primary tumor, suggesting no clonal evolution. In contrast, the mutation profiles differed in the primary tumor and lymph node/metastases samples of the remaining 11 patients (48%), suggesting a spatial and temporal clonal evolution. We confirm the presence of different mutational profiles among primary tumors, lymph node metastases and liver metastases. Our results suggest the need to perform mutational analysis in all available tumor samples of patients before deciding to commence anti-EGFR treatment. | - |
dc.description.sponsorship | This work has been partially supported by grants from the Instituto de Salud Carlos III (ISCIII; Ministerio de Sanidad y Consumo, Madrid, Spain) (PI18/00282), the Gerencia Regional de Salud de Castilla y León, Valladolid, Spain (GRS1302/A/16), the RTICC of the ISCIII (RD12/0020/0035-FEDER, RD12/0036/0048-FEDER) and CIBERONC (CB16/12/00400 and CB16/12/00233), the Fundación Memoria de Don Samuel Solórzano Barruso (Salamanca, Spain) and the Fundación Eugenio Rodríguez Pascual, (Madrid, Spain). JM Sayagués and ME Sarasquete are supported by grants (CES11/004 and CP13/00080) from the ISCIII, Ministerio de Ciencia e Innovación, Madrid, Spain. | - |
dc.language | eng | - |
dc.publisher | Impact Journals | - |
dc.relation.isversionof | Publisher's version | - |
dc.rights | openAccess | - |
dc.subject | Colorectal cancer | - |
dc.subject | Clonal evolution | - |
dc.subject | Anti-EGFR | - |
dc.subject | Mutational profiles | - |
dc.subject | Tumor heterogeneity | - |
dc.title | Spatio-temporal tumor heterogeneity in metastatic CRC tumors: A mutational-based approach | - |
dc.type | artículo | - |
dc.identifier.doi | 10.18632/oncotarget.26081 | - |
dc.relation.publisherversion | https://doi.org/10.18632/oncotarget.26081 | - |
dc.identifier.e-issn | 1949-2553 | - |
dc.date.updated | 2021-07-06T18:40:11Z | - |
dc.rights.license | http://creativecommons.org/licenses/by/3.0/ | - |
dc.contributor.funder | Instituto de Salud Carlos III | - |
dc.contributor.funder | Ministerio de Sanidad y Consumo (España) | - |
dc.contributor.funder | Junta de Castilla y León | - |
dc.contributor.funder | Fundación Memoria de D. Samuel Solorzano Barruso | - |
dc.contributor.funder | Fundación Eugenio Rodríguez Pascual | - |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | - |
dc.relation.csic | Sí | - |
dc.identifier.funder | http://dx.doi.org/10.13039/501100014180 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/100008055 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004837 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004587 | es_ES |
dc.identifier.pmid | 30344942 | - |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairetype | artículo | - |
item.fulltext | With Fulltext | - |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Spatio_Carmen_PV_Art2018.pdf | 5,81 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
12
checked on 27-abr-2024
SCOPUSTM
Citations
18
checked on 09-may-2024
Page view(s)
62
checked on 07-may-2024
Download(s)
25
checked on 07-may-2024